Table 2.
Current clinical trials in bullous pemphigoid.
| NCT number | Interventions | Target | Allocation | Masking | Phase | Status |
|---|---|---|---|---|---|---|
| NCT03099538 | Ixekizumab | IL-17 | Single group | None | 2 | Recruiting |
| NCT01408550 | NPB-1 | FcRn | Randomized | Double blind | 3 | Completed |
| NCT03286582 | AC-203 | Inflammasome | Randomized | None | 2 | Recruiting |
| NCT02226146 | Bertilimumab | eotaxin | Single group | None | 2 | Completed |
| NCT00525616 | Rituximab | CD20 | Single group | None | 3 | Completed |
No clinical trials are being performed for any other pemphigoid diseases. FcRn, neonatal Fc receptor.